April 22 (Reuters) -
* GSK & Theravance announce phase III study of FF/VI in COPD commenced to support potential future filing in Japan
* Positive results from this study will help support a potential filing of FF/VI for treatment of patients with COPD in Japan.
* Study will evaluate contribution of ICS component on lung function, in patients with chronic obstructive pulmonary disease (COPD)
* GSK chose to withdraw COPD file in Japan while designing an additional study